- $797.40m
- $767.39m
- $407.32m
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million
Brief: Ardelyx And The Lpga Announce Multi-Year Partnership
Ardelyx's 2025 net loss widens
Brief: Ardelyx Q4 Product Sales USD 114.402 Million
U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
Ardelyx rises as it begins late-stage test of constipation drug
U.S. STOCKS ON THE MOVE-Intel, Gartner, Chipotle
U.S. STOCKS ON THE MOVE-Spotify, Insmed, Nano Nuclear Energy
U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First Solar
U.S. STOCKS ON THE MOVE-Vistra, General Motors, Alphabet
Ardelyx jumps as Piper Sandler highlights strong Ibsrela uptake
U.S. RESEARCH ROUNDUP-Ardelyx, RPM International, Trubridge
Brief: Ardelyx Reports Preliminary 2025 Revenue And Provides 2026 Strategic Outlook
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
Biotech drug developer Ardelyx's Q3 product revenue rises 15%